Clinitech Lab

Has Clinitech Lab declared dividend?

No Dividend History Available

What is the technical trend for Clinitech Lab?

As of June 5, 2025, Clinitech Lab's trend is bearish with moderate strength, supported by bearish signals from Bollinger Bands and moving averages, despite a mildly bullish weekly MACD and some divergence in the OBV.

As of 5 June 2025, the technical trend for Clinitech Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD indicates a mildly bullish signal, but this is overshadowed by bearish signals from the Bollinger Bands and moving averages on the daily timeframe. Additionally, both the weekly and monthly Dow Theory confirm a bearish outlook. The OBV shows a mildly bearish trend on the weekly, while the monthly is mildly bullish, suggesting some divergence. Overall, the negative performance over the past week and month further supports the bearish sentiment.

Who are the peers of the Clinitech Lab?

Clinitech Lab's peers include Chennai Meena, Family Care, Vanta Bioscience, Gian Lifecare, Looks Health, Dr Lalchand. Lab, Dhanvantri Jeev., Ashram Online, and Sunrest Lifescie. Family Care and Sunrest Lifescie show excellent management risk, while Looks Health has the highest 1-year return at 47.37%, and Clinitech Lab's return data is unavailable.

Peers: The peers of Clinitech Lab are Chennai Meena, Family Care, Vanta Bioscience, Gian Lifecare, Looks Health, Dr Lalchand. Lab, Dhanvantri Jeev., Ashram Online, and Sunrest Lifescie.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care and Sunrest Lifescie, while Average management risk is found at Dr Lalchand. Lab. Below Average management risk is present at Gian Lifecare and Dhanvantri Jeev., and the rest do not qualify. Growth is rated as Good at Family Care and Sunrest Lifescie, Average at Gian Lifecare, and Below Average at Clinitech Lab and Dr Lalchand. Lab, while the rest do not qualify. Capital Structure is Excellent at Family Care, Good at Gian Lifecare, Dr Lalchand. Lab, and Dhanvantri Jeev., while Clinitech Lab and Sunrest Lifescie also have Good ratings, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Looks Health at 47.37%, while the lowest is Family Care at -43.73%. Clinitech Lab's 1-year return is not available for comparison. Additionally, several peers, including Gian Lifecare, Vanta Bioscience, Family Care, and Dhanvantri Jeev., have negative six-month returns.

What does Clinitech Lab do?

Clinitech Laboratory Ltd is a micro-cap company in the healthcare services industry, recently transitioned to a public limited status. It has a market cap of INR 8 Cr, a P/E ratio of 8.00, and a return on equity of 10.99%.

Overview:<BR>Clinitech Laboratory Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Clinitech Laboratory Limited was incorporated as Clinitech Laboratory Private Limited in 2010. The company changed its status to Public Limited and its name to Clinitech Laboratory Limited on August 25, 2023.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 8 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 8.00<BR>Industry P/E: N/A<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.05<BR>Return on Equity: 10.99%<BR>Price-to-Book: 2.10<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Clinitech Lab?

The top shareholders of Clinitech Lab include promoter Jyoti Jagdish Nayak with 29.57%, public shareholder Santosh Gopalkrishna Kudva with 6.2%, and individual investors collectively owning 36.28%. There is one foreign institutional investor holding 0.32%, and no mutual funds are currently invested in the company.

The top shareholders of Clinitech Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jyoti Jagdish Nayak, who owns 29.57% of the company. Additionally, the highest public shareholder is Santosh Gopalkrishna Kudva, holding 6.2%. Individual investors collectively own 36.28% of the shares, while there is one foreign institutional investor (FII) that holds 0.32%. There are currently no mutual funds holding shares in the company.

How big is Clinitech Lab?

As of 24th July, Clinitech Laboratory Ltd has a market capitalization of 7.00 Cr, classifying it as a Micro Cap company. Financial data for the latest four quarters is unavailable, but as of March 2024, Shareholder's Funds are 3.55 Cr and Total Assets are 5.44 Cr.

As of 24th July, Clinitech Laboratory Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>There is no valid financial data available for the latest four quarters, so I cannot provide information on Net Sales or Net Profit.<BR><BR>The reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 3.55 Cr and Total Assets valued at 5.44 Cr.

Is Clinitech Lab overvalued or undervalued?

As of August 28, 2025, Clinitech Lab is considered undervalued with a PE ratio of 11.41 and a low PEG ratio of 0.00, indicating a positive shift in its valuation grade to attractive, despite a year-to-date return of -36.6%, while outperforming the Sensex over the past month.

As of 28 August 2025, Clinitech Lab's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, with a PE ratio of 11.41, an EV to EBITDA ratio of 11.57, and a ROE of 10.99%. These metrics suggest that Clinitech Lab offers a compelling investment opportunity compared to its peers.<BR><BR>In the peer comparison, Clinitech Lab's PE ratio of 11.41 stands in stark contrast to Max Healthcare's exorbitant 93.61 and Apollo Hospitals' 70.56, both of which are categorized as very expensive. Additionally, Clinitech's PEG ratio is notably low at 0.00, further supporting the undervaluation narrative. While the stock has faced challenges with a year-to-date return of -36.6%, it has outperformed the Sensex over the past month, which saw a decline of 1.00%. This performance may indicate a potential recovery and growth trajectory for Clinitech Lab.

When is the next results date for Clinitech Lab?

The next results date for Clinitech Lab is 12 November 2025.

The next results date for Clinitech Lab is scheduled for 12 November 2025.

How has been the historical performance of Clinitech Lab?

Clinitech Lab's historical performance shows increasing net sales and total assets, but declining profitability metrics such as operating profit and net income over the past three years. Despite challenges in cash flow management, the company reported a net cash inflow of 2.00 Cr in Mar'25.

Answer:<BR>The historical performance of Clinitech Lab shows a mixed trend in financial metrics over the past three years.<BR><BR>Breakdown:<BR>Clinitech Lab's net sales increased from 6.35 Cr in Mar'23 to 6.40 Cr in Mar'24, and further to 8.23 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, reaching 8.23 Cr in Mar'25. However, total expenditure also rose significantly from 4.99 Cr in Mar'23 to 7.40 Cr in Mar'25, leading to a decline in operating profit (PBDIT) from 1.36 Cr in Mar'23 to 1.06 Cr in Mar'25. Profit before tax showed a decrease from 0.86 Cr in Mar'23 to 0.55 Cr in Mar'25, while profit after tax also fell from 0.61 Cr in Mar'23 to 0.39 Cr in Mar'25. Despite these declines, earnings per share (EPS) decreased from 4.07 in Mar'23 to 1.71 in Mar'25. On the balance sheet, total assets grew from 5.88 Cr in Mar'23 to 10.55 Cr in Mar'25, with total liabilities increasing from 5.88 Cr to 10.55 Cr in the same period. The company reported a net cash inflow of 2.00 Cr in Mar'25, contrasting with previous years where cash flow from operating activities was negative. Overall, Clinitech Lab's financial performance reflects growth in sales and assets but challenges in profitability and cash flow management.

Which are the latest news on Clinitech Lab?

Why is Clinitech Laboratory Ltd falling/rising?

As of 17-Mar, Clinitech Laboratory Ltd's stock price is at 33.99, down -17.1% and significantly underperforming compared to the Sensex. The stock has seen a sharp decline recently, with a total drop of -20% today and a year-to-date decrease of -19.26%, indicating a challenging environment for the company.

As of 17-Mar, Clinitech Laboratory Ltd's stock price is falling, currently at 33.99, reflecting a change of -7.01 (-17.1%). The stock has underperformed significantly, with a decline of -19.07% over the past week and -22.75% over the past month, compared to the Sensex, which has decreased by only -2.73% and -8.84% respectively. Year-to-date, the stock is down -19.26%, while the Sensex has fallen by -10.74%.<BR><BR>Today's performance indicates a particularly sharp decline, as the stock opened with a loss of -16.98% and reached an intraday low of Rs 32.8, marking a total drop of -20%. This downward trend is compounded by the fact that Clinitech Laboratory has been losing value for the last two days, with a total return of -18.1% during this period. Additionally, the stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), indicating a persistent bearish trend.<BR><BR>Investor participation has also decreased significantly, with delivery volume dropping by -76.19% compared to the 5-day average, suggesting a lack of confidence among investors. Overall, these factors contribute to the stock's decline, reflecting a challenging environment for Clinitech Laboratory Ltd.

Why is Clinitech Laboratory Ltd falling/rising?

As of 18-Mar, Clinitech Laboratory Ltd's stock price is rising to Rs 36.05, up 4.49% after a trend reversal. Despite today's gains and increased investor interest, the stock remains below its key moving averages, indicating ongoing challenges.

As of 18-Mar, Clinitech Laboratory Ltd's stock price is rising, currently at Rs 36.05, reflecting an increase of Rs 1.55 or 4.49%. This upward movement follows a trend reversal after three consecutive days of decline, indicating a potential shift in market sentiment. Today, the stock opened with a significant gain of 4.35%, and it has outperformed its sector by 3.19%. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 344.44% compared to the 5-day average, suggesting heightened interest in the stock. Despite this positive performance today, it is important to note that Clinitech Laboratory Ltd is still trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating that it has faced challenges over a longer period.

Why is Clinitech Laboratory Ltd falling/rising?

As of 19-Mar, Clinitech Laboratory Ltd's stock price is currently at 37.00, reflecting a recent upward trend with a 2.64% increase over the last two days. However, it has underperformed over the past week and month, trading below moving averages and facing a decline in investor participation.

As of 19-Mar, Clinitech Laboratory Ltd's stock price is rising, currently at 37.00, with a change of 0.95 (2.64%) upwards. This increase is notable as the stock has been gaining for the last two days, resulting in a total return of 7.25% during this period. Additionally, it has outperformed its sector by 5.46%. Despite this recent positive movement, it is important to note that the stock has been underperforming over longer periods, with declines of 10.84% over the past week and 15.91% over the past month. Furthermore, the stock is trading below its moving averages across various time frames, indicating a longer-term downward trend. The overall action in the Hospital & Healthcare Services sector has also been negative, with a decline of 2.8%. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 51.61% compared to the 5-day average. Despite these challenges, the recent gains suggest a temporary rebound in the stock's performance.

Why is Clinitech Laboratory Ltd falling/rising?

As of 20-Mar, Clinitech Laboratory Ltd's stock price is rising to Rs 38.00, reflecting a 2.7% increase. Despite recent gains and outperforming its sector, lower trading volumes and its position relative to moving averages indicate potential caution for investors.

As of 20-Mar, Clinitech Laboratory Ltd's stock price is rising, currently at Rs 38.00, reflecting a change of 1.0 (2.7%) upward. This increase can be attributed to a few key factors. Firstly, the stock has been on a positive trend, gaining for the last three days with a total return of 10.14% during this period. Additionally, it opened today with a gain of 2.7%, indicating strong initial investor interest. The stock also reached an intraday high of Rs 38.37, which is a 3.7% increase from its previous close.<BR><BR>Moreover, Clinitech Laboratory Ltd has outperformed its sector by 2.14% today, suggesting that it is attracting more attention compared to its peers. However, it is important to note that despite the recent gains, the stock is trading lower than its moving averages across various time frames, indicating potential underlying weakness. Furthermore, there has been a significant drop in investor participation, with delivery volume falling by 40% compared to the 5-day average, which could signal caution among investors.<BR><BR>In summary, while the stock is currently rising due to recent gains and positive performance relative to its sector, the overall context of lower trading volumes and its position relative to moving averages suggests that investors should remain vigilant.

Why is Clinitech Laboratory Ltd falling/rising?

As of 23-Mar, Clinitech Laboratory Ltd's stock price is at Rs 32.20, down 15.26% and underperforming its sector. The stock is in a bearish trend, trading below all major moving averages, with a significant drop in investor interest and a weekly decline of 21.46%.

As of 23-Mar, Clinitech Laboratory Ltd's stock price is falling, currently at Rs 32.20, which represents a decrease of Rs 5.8 or 15.26%. This decline is evident in the stock's performance today, where it has underperformed its sector by 12.86%. The stock opened significantly lower, with a loss of 7.84%, and reached an intraday low of Rs 32.20.<BR><BR>The stock has also shown a negative trend, having fallen after three consecutive days of gains. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Over the past week, the stock has decreased by 21.46%, while the benchmark Sensex has only fallen by 3.72%. <BR><BR>Investor participation has also declined, with delivery volume dropping by 42.31% compared to the 5-day average, suggesting reduced interest from investors. Furthermore, the broader sector of Hospital & Healthcare Services has experienced a decline of 2.37%. All these factors contribute to the current downward movement in Clinitech Laboratory Ltd's stock price.

Why is Clinitech Laboratory Ltd falling/rising?

As of 24-Mar, Clinitech Laboratory Ltd's stock price is rising to 34.95, reflecting a 6.26% increase. This rise is driven by significant investor participation and a strong intraday performance, although the stock remains below its longer-term moving averages.

As of 24-Mar, Clinitech Laboratory Ltd's stock price is rising, currently at 34.95, reflecting an increase of 2.06 or 6.26%. This upward movement is notable as the stock opened with a significant gain of 14.14% today and reached an intraday high of Rs 37.54. Additionally, the stock has outperformed its sector by 3.91%. <BR><BR>The rise in stock price can also be attributed to a substantial increase in investor participation, with a delivery volume of 32.4k on 23 March, which is up by 419.23% compared to the 5-day average delivery volume. Furthermore, the broader sector of Hospital & Healthcare Services has seen a gain of 2.48%, contributing positively to the stock's performance.<BR><BR>Despite these positive indicators, it is important to note that Clinitech Laboratory Ltd is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting that while there is a short-term rise, the stock has faced longer-term challenges. Overall, the combination of today's strong performance and increased investor interest is driving the stock's rise.

Why is Clinitech Laboratory Ltd falling/rising?

As of 25-Mar, Clinitech Laboratory Ltd's stock price is at 35.00, with a slight increase today but significant declines over the past month and year-to-date. The stock is underperforming its sector and trading below key moving averages, indicating a bearish trend and reduced investor interest.

As of 25-Mar, Clinitech Laboratory Ltd's stock price is currently at 35.00, reflecting a slight increase of 0.05 (0.14%). Despite this minor rise today, the stock has shown a significant decline over various periods, with a 1-month drop of 20.45% and a year-to-date decrease of 16.86%. <BR><BR>Today's performance indicates that the stock has underperformed its sector by 2.13%, although it has experienced gains over the last two days, totaling 6.42%. However, it is important to note that Clinitech Laboratory Ltd is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a bearish trend overall.<BR><BR>Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 71.15% compared to the 5-day average, which may indicate reduced interest in the stock. While the broader Hospital & Healthcare Services sector has gained by 2.27%, Clinitech's performance remains weak, contributing to the overall negative sentiment surrounding the stock.